European listed biotech landscape: 2019 review and outlook for 2020

2018 was a very bad year for the European biotech landscape, so the question was whether a rebound coud take place or not in 2019, in a global environment where the recurring macro themes basically remained unchanged: US/China trade war, Brexit, rates, recession fears (you know, the one that is announced every year for the[…]

The European landscape of listed biotech companies: 2018 review (Part 4)

This is the fourth part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, Part 2 or Part 3. The full report is now available here. Part 4 – Table of Content 5. Financing 6. Other financial metrics: cash burn, extra cash sources, cash balance, profits & losses   6.1[…]

The European landscape of listed biotech companies: 2018 review (Part 3)

This is the third part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, or Part 2. The full report is now available here. Part 3 – Table of Content 3. Market data   3.1 Market capitalization   3.2 Stock performances   3.3 Market Liquidity 4. Employment References 3. Market data 3.1[…]

The European landscape of listed biotech companies: 2018 review (Part 2)

This is the second part of our 2018 review dedicated to the European public biotech landscape. Check out the introduction and first part here. The full report is now available here. Part 2 – Table of Content 2. R&D Pipeline & Commercial Products   2.1 Unique product candidates in active clinical development, indications and therapeutic areas[…]

The European landscape of listed biotech companies: 2018 review (Part 1)

This review is an introduction to the universe covered by Biotellytics, publisher of biotechradar.eu, a business intelligence service on the landscape of the European biotech companies listed on the main European stock exchanges. This service aims at providing insights and data at company level for investors, as well as consolidated data at the European level[…]